[ad_1]
It is estimated that by 2030, this disease will be the third leading cause of death, so that access to innovative and timely treatments are essential to treat this health problem.
In a press conference, Jesus Javier Vázquez Cortés, a member of the Mexican Society of Pneumology and Surgical Surgery (SMNyCT), said that this condition usually occurs in people over the age of 40, and it is estimated that In Mexico, it affects 7.9 per cent of the population.
"As the disease progresses, patients experience xacerbations, that is, intense episodes of dyspnea, coughing, and expectoration that can last for days or weeks. and who sometimes require hospitalization, "he said
Development made possible a new therapeutic option
This is a triple therapy consisting of inhaled steroids and bronchodilators long-acting, which reduce the risk of moderate-to-severe exacerbations of up to 25%.
[ad_2]
Source link